FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3209606623> ?p ?o ?g. }

• W3209606623 endingPage "199" @default.
• W3209606623 startingPage "187" @default.
• W3209606623 abstract "Colistin is used to treat severe antibiotic-resistant Gram-negative infections (GNIs). With the rise of antibiotic resistance, colistin has been used increasingly as a 'last-line' therapy for multidrug-resistant GNIs. We evaluated the incidence of acute kidney injury (AKI) and mortality among patients receiving colistin or one of the new β-lactam/β-lactamase inhibitors (βL + βLI) (ceftazidime/avibactam, ceftolozane/tazobactam, or meropenem/vaborbactam).This retrospective cohort study used data from the Premier Healthcare Database. The cohort included propensity score-matched adults with an inpatient stay between January 2016 and December 2018. Patients given both colistin and BL + BLI as treatment for ≥ 72 h were excluded. AKI was defined as acute renal failure or dialysis during hospitalization with antibiotic administration. Propensity score matching was used to control for selection bias and confounding. Logistic regression evaluated associations between treatment, AKI, and in-hospital mortality.The total number of patients in the matched cohorts were 256 in each. Overall, 23.8% and 13.3% of patients receiving colistin or new βL + βLI agents, respectively, experienced AKI during hospitalization (p = 0.002); odds of AKI for colistin were 3.0 (95% CI 1.71, 5.21). Following propensity score-matching, patients without baseline renal disease experienced AKI during hospitalization to a higher degree in the colistin group compared to the βL + βLI group (17.1% vs. 6.8%); colistin use was associated with 3.7 times higher odds (95% CI 1.84, 7.42) of AKI compared to βL + βLI agents. The odds of mortality in patients on colistin developing AKI were more than three times that of patients receiving a BL + BLI agent who developed AKI. Among patients receiving colistin, incident AKI was associated with 6.1 times higher odds (95% CI 2.53, 14.71) of mortality.Patients receiving colistin for GNIs had significantly higher odds of AKI and mortality than those receiving βL + βLI." @default.
• W3209606623 created "2021-11-08" @default.
• W3209606623 creator A5028123620 @default.
• W3209606623 creator A5044329034 @default.
• W3209606623 creator A5050331950 @default.
• W3209606623 creator A5060214913 @default.
• W3209606623 date "2021-11-03" @default.
• W3209606623 modified "2023-09-26" @default.
• W3209606623 title "Utilization of Colistin Versus β-Lactam and β-Lactamase Inhibitor Agents in Relation to Acute Kidney Injury in Patients with Severe Gram-Negative Infections" @default.
• W3209606623 cites W2000445173 @default.
• W3209606623 cites W2047015206 @default.
• W3209606623 cites W2126332577 @default.
• W3209606623 cites W2129168200 @default.
• W3209606623 cites W2145705966 @default.
• W3209606623 cites W2496872689 @default.
• W3209606623 cites W2515155615 @default.
• W3209606623 cites W2593444269 @default.
• W3209606623 cites W2766370714 @default.
• W3209606623 cites W2769645739 @default.
• W3209606623 cites W2791776064 @default.
• W3209606623 cites W2792522229 @default.
• W3209606623 cites W2895593384 @default.
• W3209606623 cites W2900768728 @default.
• W3209606623 cites W2901454701 @default.
• W3209606623 cites W2968244461 @default.
• W3209606623 cites W2972411914 @default.
• W3209606623 cites W2986534514 @default.
• W3209606623 cites W2998944567 @default.
• W3209606623 cites W3043930722 @default.
• W3209606623 cites W3047390121 @default.
• W3209606623 cites W3126098334 @default.
• W3209606623 doi "https://doi.org/10.1007/s40121-021-00556-x" @default.
• W3209606623 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8564277" @default.
• W3209606623 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34731456" @default.
• W3209606623 hasPublicationYear "2021" @default.
• W3209606623 type Work @default.
• W3209606623 sameAs 3209606623 @default.
• W3209606623 citedByCount "5" @default.
• W3209606623 countsByYear W32096066232021 @default.
• W3209606623 countsByYear W32096066232022 @default.
• W3209606623 countsByYear W32096066232023 @default.
• W3209606623 crossrefType "journal-article" @default.
• W3209606623 hasAuthorship W3209606623A5028123620 @default.
• W3209606623 hasAuthorship W3209606623A5044329034 @default.
• W3209606623 hasAuthorship W3209606623A5050331950 @default.
• W3209606623 hasAuthorship W3209606623A5060214913 @default.
• W3209606623 hasBestOaLocation W32096066231 @default.
• W3209606623 hasConcept C126322002 @default.
• W3209606623 hasConcept C156957248 @default.
• W3209606623 hasConcept C167135981 @default.
• W3209606623 hasConcept C17923572 @default.
• W3209606623 hasConcept C2776685102 @default.
• W3209606623 hasConcept C2777637488 @default.
• W3209606623 hasConcept C2777858937 @default.
• W3209606623 hasConcept C2778193466 @default.
• W3209606623 hasConcept C2779259085 @default.
• W3209606623 hasConcept C2780472472 @default.
• W3209606623 hasConcept C501593827 @default.
• W3209606623 hasConcept C523546767 @default.
• W3209606623 hasConcept C54355233 @default.
• W3209606623 hasConcept C71924100 @default.
• W3209606623 hasConcept C72563966 @default.
• W3209606623 hasConcept C86803240 @default.
• W3209606623 hasConcept C89423630 @default.
• W3209606623 hasConceptScore W3209606623C126322002 @default.
• W3209606623 hasConceptScore W3209606623C156957248 @default.
• W3209606623 hasConceptScore W3209606623C167135981 @default.
• W3209606623 hasConceptScore W3209606623C17923572 @default.
• W3209606623 hasConceptScore W3209606623C2776685102 @default.
• W3209606623 hasConceptScore W3209606623C2777637488 @default.
• W3209606623 hasConceptScore W3209606623C2777858937 @default.
• W3209606623 hasConceptScore W3209606623C2778193466 @default.
• W3209606623 hasConceptScore W3209606623C2779259085 @default.
• W3209606623 hasConceptScore W3209606623C2780472472 @default.
• W3209606623 hasConceptScore W3209606623C501593827 @default.
• W3209606623 hasConceptScore W3209606623C523546767 @default.
• W3209606623 hasConceptScore W3209606623C54355233 @default.
• W3209606623 hasConceptScore W3209606623C71924100 @default.
• W3209606623 hasConceptScore W3209606623C72563966 @default.
• W3209606623 hasConceptScore W3209606623C86803240 @default.
• W3209606623 hasConceptScore W3209606623C89423630 @default.
• W3209606623 hasFunder F4320323316 @default.
• W3209606623 hasIssue "1" @default.
• W3209606623 hasLocation W32096066231 @default.
• W3209606623 hasLocation W32096066232 @default.
• W3209606623 hasLocation W32096066233 @default.
• W3209606623 hasOpenAccess W3209606623 @default.
• W3209606623 hasPrimaryLocation W32096066231 @default.
• W3209606623 hasRelatedWork W2915041500 @default.
• W3209606623 hasRelatedWork W2973059042 @default.
• W3209606623 hasRelatedWork W3014075454 @default.
• W3209606623 hasRelatedWork W3086277170 @default.
• W3209606623 hasRelatedWork W3126332138 @default.
• W3209606623 hasRelatedWork W3209606623 @default.
• W3209606623 hasRelatedWork W4235834539 @default.
• W3209606623 hasRelatedWork W4294168904 @default.
• W3209606623 hasRelatedWork W4294990527 @default.
• W3209606623 hasRelatedWork W4297235855 @default.

• next